Ambrilia Biopharma Inc.

Ambrilia Biopharma Inc.

December 10, 2007 09:02 ET

Ambrilia Appoints Dr. St-Pierre to its Board of Directors.

MONTREAL, QUEBEC--(Marketwire - Dec. 10, 2007) - Ambrilia Biopharma Inc. (TSX:AMB) announced today that Jean-Paul St-Pierre, M.D., has joined the Board of Directors of the Company.

"I wish to welcome Dr. St-Pierre, who is a talented executive in drug research and development management in the biotechnology and pharmaceutical industries, as a new member of the Board", said Frederic Porte, Chairman of the Board of Ambrilia. "His know-how in building and maximizing R&D capabilities as well as his expertise in design and implementation of drug discovery and development strategies will be value-added assets to Ambrilia's execution of its new strategic plan", he concluded.


Dr. St-Pierre is a seasoned executive with more than 20 years of experience in managing global research and drug development within the pharmaceutical and biotechnology industries. He is also an accomplished clinical researcher since 1971 in therapeutic areas such as allergy, immunology, anti-infective, cardiovascular, endocrinology and others. During his career, he was responsible for overseeing the North American and Latin American clinical operations at Wyeth Pharmaceuticals. He was also Co-Chairman of the Global Monitoring Committee, responsible for the clinical trials assignment for the global Wyeth organization. Dr. St-Pierre was Vice-President of the worldwide clinical development operations at Rhone-Poulenc (U.S), where he designed and successfully implemented a management structure for worldwide clinical operations and which included all resources allocation. At Hoechst Marion Roussel Canada, Dr. St-Pierre was Executive Vice-President, Scientific Affairs, during which time he integrated the scientific activities of Hoechst Roussel and Marion Merrell Dow.

He spent 7 years at Sandoz Canada where he occupied several executive positions and became Vice-President, Scientific Development and where he built a strong research team. Dr. St-Pierre was President and CEO of Synapse Technologies where he implemented 2 business plans and secured financing with investors in Canada, the U.S. and Europe. He also designed and developed IND programs for lead discoveries.

A specialist in allergy and clinical immunology, he currently runs a medical practice at the Montreal St-Justine Hospital and is an active consultant in biotechnology. He received his M.D. from the University of Montreal and did a Fellowship in Allergy and Immunology at the University of Colorado and is a Board certified in allergy and immunology in the U.S.


This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein and depend on a number of factors including, but not limited to, changing market conditions, successful and timely completion of clinical studies, uncertainties related to the regulatory approval process, establishment of corporate alliances and other risks detailed from time to time in the Company's filings. We refer you to the Risk Factors section of the Company's Management's Discussion & Analysis of Financial Condition and Results of Operations which contain a more exhaustive analysis of the risks and uncertainties that are generally connected to the business of the Company. Such statements are also based on various assumptions, including the successful and timely completion of clinical studies on Ambrilia's products demonstrating efficacy and safety for human use, their successful commercialization within the forecasted timelines and the attainment of the forecasted milestone payments and other revenues. While Ambrilia anticipates that subsequent events and developments may cause Ambrilia's views to change, Ambrilia specifically disclaims any obligation to update these forward looking statements, unless obligated to do so by applicable securities laws.


Ambrilia Biopharma Inc. (TSX:AMB) is a biopharmaceutical company dedicated to the discovery and development of novel treatments for viral diseases and cancer. Ambrilia's product portfolio includes an HIV protease inhibitor program (with lead compound PPL-100), an HIV integrase inhibitor program, two new formulations of existing peptides (Octreotide and Goserelin), other tumor targeted peptides such as PCK3145 and the Tumor and tumor Vasculature Targeting (TVT) technology platform, as well as other anti-viral programs. Exclusive worldwide rights to PPL-100 and its related compounds have been granted to Merck & Co., Inc. in return for milestone payments and royalties. Ambrilia's head office, research and development and manufacturing facilities are located in Montreal with a regional office in France. For more information, please visit the Company's web site:

Contact Information